Alvita Pharma Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Alvita Pharma Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $478.8K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Alvita Pharma Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $478.8K Trade | TransData Nexus

Alvita Pharma Private Limited

Indian Pharmaceutical Exporter · Gastrointestinal Specialist · $478.8K Total Trade · DGFT Verified

Alvita Pharma Private Limited is an Indian pharmaceutical exporter with a total trade value of $478.8K across 2 products in 2 therapeutic categories. Based on 17 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Lactulose ($243.0K), Moxifloxacin ($235.8K), .

Alvita Pharma Private Limited — Export Portfolio & Destination Treemap

Alvita Pharma Private Limited pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Alvita Pharma Private Limited? — Company Overview & Market Position

Alvita Pharma Private Limited, established on January 23, 2010, is a privately held pharmaceutical company headquartered in Mumbai, India. The company is registered under the Corporate Identification Number (CIN) U24230GJ2010PTC059305, with its registered office located at B-203, Gopal Palace, Near Nehru Nagar Circle, Satellite Road, Ambavadi, Ahmedabad, Gujarat, 380015.

The authorized capital of Alvita Pharma is ₹100 million, with a paid-up capital of ₹90 million. As of the latest available data, the company employs between 11 to 50 individuals. Alvita Pharma specializes in the manufacturing of pharmaceutical products, including tablets, capsules, syrups, and injections, across various therapeutic categories.

What Does Alvita Pharma Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Lactulose$243.0K 2Moxifloxacin$235.8K

Product Portfolio — Top 2 by Export Value

Alvita Pharma Private Limited exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Lactulose	Gastrointestinal	$243.0K	9	1.8%	8
2	Moxifloxacin	Advanced Antibiotics	$235.8K	8	0.7%	15

Alvita Pharma Private Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $478.8K. The top category is Gastrointestinal (50.8% of portfolio), followed by Advanced Antibiotics (49.2%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Alvita Pharma Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Alvita Pharma operates manufacturing facilities in Mumbai and Vadodara, Gujarat. The Vadodara unit is fully operational and was expected to obtain European Union approval by March 2023. These facilities are equipped to produce a wide range of finished pharmaceutical formulations, ensuring compliance with international quality standards.

3Key Leadership

The leadership team at Alvita Pharma includes:

Surendra Kumar Lohia: Director
Manoj Ramaniklal Vora: Director
Sajan Parmeswaran Unnithan: Director

These individuals play pivotal roles in steering the company's strategic direction and operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Alvita Pharma Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Alvita Pharma has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing unit in Vadodara was anticipated to receive European Union approval by March 2023, indicating its commitment to meeting stringent international regulatory standards. While specific details regarding regulatory filings and approvals in other markets are not publicly disclosed, Alvita Pharma's adherence to EU GMP standards suggests a proactive approach to obtaining necessary certifications for these regions.

2Emerging Markets

Alvita Pharma has expanded its footprint into emerging markets across Africa, Southeast Asia, and Eastern Europe. The company markets over 600 products in therapeutic segments such as anti-malarial, gastrointestinal, antibiotics, cardiology, dermatology, and pain management. This diverse portfolio enables Alvita Pharma to address the healthcare needs of various populations, leveraging WHO prequalification to enhance access to quality medicines in these regions.

3Geographic Strategy

Alvita Pharma Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Alvita Pharma's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. However, the company's commitment to obtaining European Union approval for its Vadodara manufacturing unit by March 2023 suggests a proactive approach to meeting international regulatory standards, which may include FDA requirements.

2WHO & EU GMP

Alvita Pharma's Vadodara manufacturing unit was expected to obtain European Union approval by March 2023, indicating compliance with EU Good Manufacturing Practice (GMP) standards. While specific details regarding WHO prequalification are not publicly disclosed, the company's adherence to EU GMP standards suggests a commitment to meeting international quality benchmarks.

3CDSCO & Indian Regulatory

Alvita Pharma holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and has obtained approvals from state drug controllers. The company has also secured export No Objection Certificates (NOCs), facilitating its international trade operations. These regulatory compliances underscore Alvita Pharma's commitment to maintaining high-quality manufacturing standards and adhering to Indian regulatory requirements.

Alvita Pharma Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Alvita Pharma operates in a competitive landscape alongside major pharmaceutical companies such as Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Ltd., Cipla Ltd., Zydus Lifesciences Ltd., and Lupin Ltd. While Alvita Pharma's market share in overlapping categories is not publicly disclosed, its focus on branded generics and diverse therapeutic segments positions it to compete effectively in both domestic and international markets.

2Key Differentiators

Alvita Pharma's key differentiators include its extensive product portfolio of over 600 products across various therapeutic segments, advanced research facilities in Mumbai and Vadodara, and a commitment to launching first-to-market products in different countries. These strengths enable the company to provide high-quality and affordable medicines to a diverse patient base.

3Strategic Position

Alvita Pharma's current strategic direction focuses on expanding its branded generic business across Africa, Southeast Asia, and Eastern Europe. The company is actively involved in business development and licensing to launch innovative molecules and formulations in the Indian market. Looking ahead, Alvita Pharma aims to strengthen its global presence by leveraging its manufacturing capabilities and diverse product portfolio to meet the evolving healthcare needs of various regions.

Buyer Due Diligence Brief — Evaluating Alvita Pharma Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Alvita Pharma has demonstrated a consistent track record in manufacturing and exporting pharmaceutical products, with a total export value of $479,000 USD across 17 shipments. The company's portfolio concentration, with its top five products accounting for 100% of exports, indicates a focused approach to its product offerings. The proactive steps taken to obtain European Union approval for its Vadodara manufacturing unit by March 2023 further underscore its commitment to quality and compliance.

2Certifications to Verify

Importers should verify the following certifications when considering Alvita Pharma as a supplier:

FDA Registration: Confirm the company's FDA facility registration status through the FDA's official website.
WHO-GMP Certification: Check the World Health Organization's official website for prequalification status.
EU GMP Certification: Verify the European Medicines Agency's website for GMP compliance status.

Frequently Asked Questions — Alvita Pharma Private Limited

How many pharmaceutical products does Alvita Pharma Private Limited export from India?

Alvita Pharma Private Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Lactulose ($243.0K), Moxifloxacin ($235.8K). Total export value is $478.8K.

What is Alvita Pharma Private Limited's total pharmaceutical export value?

Alvita Pharma Private Limited's total pharmaceutical export value is $478.8K, based on 17 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Alvita Pharma Private Limited cover?

Alvita Pharma Private Limited exports across 2 therapeutic categories. The largest are Gastrointestinal (50.8%, 1 products), Advanced Antibiotics (49.2%, 1 products).

Get Full Alvita Pharma Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.